according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Alvimopan Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

+1-908-423-6000

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

EUH210 Safety data sheet available on request.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Alvimopan	170098-38-1	Acute Tox. 4; H302	>= 1 - < 10

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

**SECTION 5: Firefighting measures** 

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

 Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

**SECTION 6: Accidental release measures** 

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Dust 5 mg/m3

Value type (Form of exposure): TWA (respirable dust)

Basis: FOR-2011-12-06-1358

10 mg/m3

Value type (Form of exposure): TWA (total dust)

Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Alvimopan	170098-38- 1	TWA	10 μg/m3	Internal
		Wipe limit	100 μg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### **Engineering measures**

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

### Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:

Safety goggles

Equipment should conform to NS EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : For prolonged or repeated contact use protective gloves.

Wash hands before breaks and at the end of workday.

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Equipment should conform to NS EN 143

Filter type : Particulates type (P)

### **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Vapour pressure : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Alvimopan Formulation

Date of last issue: 06.04.2024 Version Revision Date: SDS Number: 2.3 28.09.2024 657616-00021 Date of first issue: 02.05.2016

### **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

**Components:** 

Alvimopan:

Acute oral toxicity : LD50 (Rat): > 500 mg/kg

LD50 (Mouse): > 4.000 mg/kg

Acute dermal toxicity LD50 (Mouse): > 2.000 mg/kg

Acute toxicity (other routes of :

LD50 (Rat): > 20 mg/kg

Application Route: Intravenous administration)

Remarks: No significant adverse effects were reported

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Alvimopan:

**Species** Rabbit

Mild skin irritation Result

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Alvimopan:

**Species** Rabbit

Result Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Alvimopan:

Test Type **Maximisation Test** 

Exposure routes Dermal Result negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657616-00021 Date of first issue: 02.05.2016

### Germ cell mutagenicity

Not classified based on available information.

### **Components:**

Alvimopan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse Application Route: Oral Result: negative

### Carcinogenicity

Not classified based on available information.

#### Components:

### Alvimopan:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 500 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

LOAEL : 4.000 mg/kg body weight

Result : positive Target Organs : Bone, Skin

Remarks : Benign and malignant tumor(s)

Adverse effects were observed in females only.

There is no evidence that these findings are relevant to hu-

mans.

#### Reproductive toxicity

Not classified based on available information.

### **Components:**

### Alvimopan:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection Fertility: NOAEL: 5 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL: 200 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rabbit

Application Route: Intravenous

Fertility: NOAEL: 15 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 100 mg/kg body weight

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 200 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: No significant adverse effects were reported

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 15 mg/kg body weight Result: No significant adverse effects were reported

### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

### **Components:**

#### Alvimopan:

Species : Mouse

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657616-00021 Date of first issue: 02.05.2016

NOAEL : 1000 mg/kg

Application Route : Oral Exposure time : 13 Weeks

Remarks : No significant adverse effects were reported

Species : Dog

NOAEL : 1000 mg/kg

Application Route : Oral Exposure time : 39 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 1 yr

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 2 mg/kg
Application Route : Intravenous
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

### **Aspiration toxicity**

Not classified based on available information.

### 11.2 Information on other hazards

### **Endocrine disrupting properties**

### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### Experience with human exposure

### **Components:**

Alvimopan:

Ingestion : Symptoms: stomach discomfort, Gastrointestinal disturbance,

Nausea, Vomiting, Abdominal pain

### **SECTION 12: Ecological information**

### 12.1 Toxicity

#### **Components:**

#### Alvimopan:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657616-00021
 Date of first issue: 02.05.2016

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 17 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 17 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Scenedesmus subspicatus): > 17 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Scenedesmus subspicatus): 17 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 920 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 920 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

### 12.2 Persistence and degradability

#### **Components:**

Alvimopan:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 4 % Exposure time: 28 d

#### 12.3 Bioaccumulative potential

### Components:

Alvimopan:

Partition coefficient: n-

log Pow: 0,52

octanol/water

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### **Product:**

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657616-00021 Date of first issue: 02.05.2016

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

### 12.6 Endocrine disrupting properties

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 657616-00021 Date of first issue: 02.05.2016

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657616-00021 Date of first issue: 02.05.2016

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H302 : Harmful if swallowed.

Full text of other abbreviations

Acute Tox. : Acute toxicity

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Re-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Alvimopan Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 06.04.2024 2.3 28.09.2024 657616-00021 Date of first issue: 02.05.2016

striction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN